COVID-19 Drinking medicine, also effective for "Stealth Omicron" = Korea

The Korea National Institute of Health, Korea National Institute of Health announced on May 6th that the BA.1, BA.1, BA.2 virus, which is a detailed type of Omicron strain, was targeted for the oral drugs "Paxlobido" and "Lagebrio" introduced in South Korea. As a result of evaluating the antiviral efficacy against, it was announced that the efficacy would be maintained. Of these, BA.2 means stealth omicron, which is more infectious than BA.1, which is often called omicron.

As a result of the analysis, it was judged that the antiviral efficacy against the detailed strain of Omicron was 0.7 to 2.4 times higher than the efficacy against the Delta strain, but the efficacy was maintained.

The laboratory reported that Bekulley (ingredient name: remdesivir), which is being used as an injection, also confirmed that the antiviral efficacy against the detailed strain of Omicron was maintained.

Kwon Jun-wook, director of the National Institute of Health, said, "We plan to continuously evaluate the efficacy of therapeutic drugs in use in Japan when a COVID-19 virus mutant strain occurs." Through cooperation with the anti-virus base laboratory, we will strengthen our ability to develop therapeutic drugs, such as advancing the technology for searching for therapeutic drugs."